Novavax Inc's COVID-19 vaccine NVX-CoV2373 demonstrated 90.4% overall efficacy against SARS-CoV-2 infection, and 100% protection against moderate and severe disease, according to a Phase 3 PREVENT-19 clinical trial.
The FDA approved sotorasib (Lumakras, Amgen Inc) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C.
A five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.
Read More
The US FDA has revoked an EUA for the monoclonal antibody bamlanivimab when administered alone, for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
Read More
The US FDA has approved Genetech’s Xolair (omalizumab) prefilled syringe for self-injection for the treatment of moderate to severe persistent allergic asthma, chronic idiopathic urticaria, and nasal polyps.
Read More
According to data tracked by the CDC, women accounted for 79% of all adverse reactions reported for the Moderna and Pfizer COVID-19 vaccines over a one-month period.
Read More
Regen-CoV — a monoclonal antibody cocktail from Regeneron — reduced the risk of symptomatic SARS-CoV-2 infections by 81% in a Phase 3 clinical trial.
Read More
Updated Phase 3 data analyzing the Pfizer-BioNTech COVID-19 vaccine up to six months after second vaccination showed it was 91.3% effective overall and 100% effective versus severe disease.
Read More
Results of a Phase 3 trial of Pfizer/BioNTech’s COVID-19 vaccine demonstrated a 100% efficacy and robust antibody responses in participants aged 12-15 years old, according to the company.
Read More
According to a study published in AJRCCM, Vertex Pharma’s Trikafta...
Read More
The CDC reports risk of COVID-19 infection following the second dose of Moderna or Pfizer’s vaccine was reduced by 90% two or more weeks after vaccination.
Read More
New data released by AstraZeneca Thursday report its vaccine was 76% effective at overall prevention of symptomatic COVID-19, 85% effective in adults 65 and older, and 100% effective in preventing severe or critical disease and hospitalization.
Read More
A Data & Safety Monitoring Board expressed concern that AstraZeneca may have included outdated information in a Phase 3 trial for its COVID-19 vaccine.
Read More
AstraZeneca says it will submit its COVID-19 vaccination for FDA authorization after phase 3 trial results found the vaccine to be 79% effective at preventing symptomatic COVID-19 and 100% effective at preventing severe disease and hospitalization.
Read More